Darifenacin Hydrobromide Patent Expiration
Darifenacin Hydrobromide is Used for treating a disease of altered motility or tone of smooth muscle and urinary incontinence. It was first introduced by Abbvie Inc
Darifenacin Hydrobromide Patents
Given below is the list of patents protecting Darifenacin Hydrobromide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Enablex | US6106864 | Pharmaceutical formulations containing darifenacin |
Aug 21, 2016
(Expired) | Abbvie |
| Enablex | US5096890 | Pyrrolidine derivatives |
Mar 13, 2015
(Expired) | Abbvie |
Darifenacin Hydrobromide's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List